Yuheng Jin

Hangzhou, 310058, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Modular PROTAC/IMiD Bifunctional Molecule Design for the Degradation of Synergistic Targets in the Treatment of Lymphoma.

Modular PROTAC/IMiD Bifunctional Molecule Design for the Degradation of Synergistic Targets in the Treatment of Lymphoma.

Journal: Journal of medicinal chemistry

Published: October 14, 2025

Discovery of a Selective and Potent BCL6 PROTAC with Efficacious Antiproliferative Activity for the Treatment of Diffuse Large B-Cell Lymphoma.

Discovery of a Selective and Potent BCL6 PROTAC with Efficacious Antiproliferative Activity for the Treatment of Diffuse Large B-Cell Lymphoma.

Journal: Journal of medicinal chemistry

Published: September 30, 2025

Auto-RapTAC: A Versatile and Sustainable Platform for the Automated Rapid Synthesis and Evaluation of PROTAC.

Auto-RapTAC: A Versatile and Sustainable Platform for the Automated Rapid Synthesis and Evaluation of PROTAC.

Journal: Journal of medicinal chemistry

Published: January 04, 2025

Discovery of a Novel Non-invasive AR PROTAC Degrader for the Topical Treatment of Androgenetic Alopecia.

Discovery of a Novel Non-invasive AR PROTAC Degrader for the Topical Treatment of Androgenetic Alopecia.

Journal: Journal of medicinal chemistry

Published: December 06, 2024

Exploration of the convergence of the three foot-yin meridians at Sanyinjiao (SP6)

Exploration of the convergence of the three foot-yin meridians at Sanyinjiao (SP6)

Journal: Zhongguo zhen jiu = Chinese acupuncture & moxibustion

Published: November 25, 2024

Discovery of a potential hematologic malignancies therapy: Selective and potent HDAC7 PROTAC degrader targeting non-enzymatic function.

Discovery of a potential hematologic malignancies therapy: Selective and potent HDAC7 PROTAC degrader targeting non-enzymatic function.

Journal: Acta pharmaceutica Sinica. B

Published: September 08, 2024

Discovery of an Exceptionally Orally Bioavailable and Potent HPK1 PROTAC with Enhancement of Antitumor Efficacy of Anti-PD-L1 Therapy.

Discovery of an Exceptionally Orally Bioavailable and Potent HPK1 PROTAC with Enhancement of Antitumor Efficacy of Anti-PD-L1 Therapy.

Journal: Journal of medicinal chemistry

Published: July 31, 2024

Discovery of New Phenyltetrazolium Derivatives as Ferroptosis Inhibitors for Treating Ischemic Stroke: An Example Development from Free Radical Scavengers.

Discovery of New Phenyltetrazolium Derivatives as Ferroptosis Inhibitors for Treating Ischemic Stroke: An Example Development from Free Radical Scavengers.

Journal: Journal of medicinal chemistry

Published: July 12, 2024

Structure-based identification of new orally bioavailable BRD9-PROTACs for treating acute myelocytic leukemia.

Structure-based identification of new orally bioavailable BRD9-PROTACs for treating acute myelocytic leukemia.

Journal: European journal of medicinal chemistry

Published: August 09, 2023

Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.

Structural Feature Analyzation Strategies toward Discovery of Orally Bioavailable PROTACs of Bruton's Tyrosine Kinase for the Treatment of Lymphoma.

Journal: Journal of medicinal chemistry

Published: June 07, 2022

Showing 1-10 of 10

Last Updated: 09/26/2026